Cargando…
Regulatory enforcement of the marketing of fixed-dose combinations in India: a case study of systemic antibiotics
BACKGROUND: In India, states have licensed the manufacture of large numbers of fixed-dose combination (FDC) drugs without the required prior approval of the central regulator. This paper describes two major regulatory initiatives to address the problem, which began in 2007 and 2013, and examines whe...
Autores principales: | Brhlikova, Petra, Mehta, Aashna, McGettigan, Patricia, Pollock, Allyson M., Roderick, Peter, Farooqui, Habib Hasan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10636890/ https://www.ncbi.nlm.nih.gov/pubmed/37950272 http://dx.doi.org/10.1186/s40545-023-00644-y |
Ejemplares similares
-
Systemic antibiotic sales and WHO recommendations, India
por: Mehta, Aashna, et al.
Publicado: (2022) -
Use of Fixed Dose Combination (FDC) Drugs in India: Central Regulatory Approval and Sales of FDCs Containing Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Metformin, or Psychotropic Drugs
por: McGettigan, Patricia, et al.
Publicado: (2015) -
Outpatient antibiotic prescription rate and pattern in the private sector in India: Evidence from medical audit data
por: Farooqui, Habib Hasan, et al.
Publicado: (2019) -
A Critical Analysis of Concentration and Competition in the Indian Pharmaceutical Market
por: Mehta, Aashna, et al.
Publicado: (2016) -
Community level antibiotic utilization in India and its comparison vis-à-vis European countries: Evidence from pharmaceutical sales data
por: Farooqui, Habib Hasan, et al.
Publicado: (2018)